News
CSLLY
24.24
-0.98%
-0.24
Is CSL An Unmissable Value Play?
Seeking Alpha · 1h ago
Weekly Report: what happened at CSLLY last week (0803-0807)?
Weekly Report · 3d ago
Weekly Report: what happened at CSLLY last week (0727-0731)?
Weekly Report · 08/03 10:03
UBS Sticks to Its Buy Rating for CSL (CMXHF)
TipRanks · 07/31 13:36
Bell Potter Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 07/31 00:05
CSL (CMXHF) Gets a Hold from Jefferies
TipRanks · 07/29 12:46
Weekly Report: what happened at CSLLY last week (0720-0724)?
Weekly Report · 07/27 10:06
Ord Minnett Reaffirms Their Hold Rating on CSL (CMXHF)
TipRanks · 07/23 00:35
Weekly Report: what happened at CSLLY last week (0713-0717)?
Weekly Report · 07/20 10:03
RBC Capital Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 07/18 01:47
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q2
Seeking Alpha · 07/17 13:35
Citi Remains a Hold on CSL (CMXHF)
TipRanks · 07/15 00:35
Weekly Report: what happened at CSLLY last week (0706-0710)?
Weekly Report · 07/13 10:05
Sanofi offers to stop disparaging CSL’s flu vaccine after EU probe
Seeking Alpha · 07/08 15:57
My Top 5 Pharma Stocks Wall Street Ignores
Seeking Alpha · 07/06 13:55
Weekly Report: what happened at CSLLY last week (0629-0703)?
Weekly Report · 07/06 10:08
UBS Reaffirms Their Buy Rating on CSL (CMXHF)
TipRanks · 07/01 00:05
CSL (CMXHF) Receives a Hold from Ord Minnett
TipRanks · 06/30 01:35
Macquarie Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 06/30 00:06
Weekly Report: what happened at CSLLY last week (0622-0626)?
Weekly Report · 06/29 10:04
More
Webull provides a variety of real-time CSLLY stock news. You can receive the latest news about Csl Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CSLLY
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.